FDA requires lower dosing of zolpidem

Medical Letter on Drugs and Therapeutics

Volumn 55, Issue 1408, 2013, Pages 5-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

INTERMEZZO; UNCLASSIFIED DRUG; ZOLPIDEM TARTRATE;

ANTEROGRADE AMNESIA; DEPENDENT PERSONALITY DISORDER; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG RELEASE; DRUG SAFETY; FALLING; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; INSOMNIA; LETTER; RECOMMENDED DRUG DOSE; RISK; SLEEP DISORDER;

AUTOMOBILE DRIVING; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PYRIDINES; SEX FACTORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TASK PERFORMANCE AND ANALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84872728086     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar and Zolpimist). Available at www.fda.gov/Drugs/DrugSafety/ucm334033.htm. Accessed January 14, 2013.
2. Low-dose sublingual zolpidem (Intermezzo) for insomnia due to middle-of-the-night awakening. Med Lett Drugs Ther 2012; 54:25.
3. Drugs for insomnia.Treat Guidel Med Lett 2012; 10:57.